loader image
Monday, June 23, 2025
81.1 F
McAllen
We Welcome your Press Release
- Advertisement -

New Alzheimer’s Drug Receives Full FDA Approval

Translate to Spanish or other 102 languages!

The medication, which is called lecanemab, was designed to reduce amyloid beta plaque in the brain. Image for illustration purposes
The medication, which is called lecanemab, was designed to reduce amyloid beta plaque in the brain. Image for illustration purposes

Mega Doctor News

- Advertisement -

CLEVELAND CLINIC – According to the Centers for Disease Control and Prevention (CDC), an estimated 6.5 million Americans are living with Alzheimer’s disease, which does not have a cure.

However, researchers are hopeful about a new medication that was recently approved by the Food and Drug Administration (FDA) for people with early-stage disease.

“When we say Alzheimer’s, it’s a large spectrum, so there are very early stages to very advanced dementia,” said Babak Tousi, MD, neurogeriatrician for Cleveland Clinic. “So, at this point, there are no findings supporting the use of this medication for people with moderate to late-stage dementia. This is for people in the very early stages of the disease.”

- Advertisement -

The medication, which is called lecanemab, was designed to reduce amyloid beta plaque in the brain.

Amyloid beta plaque has been linked to Alzheimer’s disease.

Dr. Tousi explained that the medication does not treat symptoms of the disease but rather helps to slow the progression of it.

As far as success rates go, results from an 18-month clinical trial showed participants who received the medication had a 27 percent reduction in amyloid beta plaque.

- Advertisement -

Dr. Tousi said that number may sound small, but he believes it’s a good place to start.

“It seems we have achieved some treatment. We can affect the disease trajectory. It is a small benefit, but it’s still a benefit,” he said. “We can slow it down and I think it’s one of many to come down the road to hopefully target it, so that’s the biggest step for us.”

Documented side effects for the medication included micro-hemorrhages and edema, which is accumulation of fluid in brain tissue.

Editor’s note: Dr. Tousi is a paid scientific advisor for Biogen and Eisai.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Inside DHR Health’s DTOR Breakthrough

Mega Doctor News By Roberto Hugo González An ambitious trauma initiative quietly redefines...

Terracon Foundation Grant Supports Upgrades to Pediatric Therapy Spaces at Moody Clinic

Mega Doctor News PHARR, TEXAS – The Terracon Foundation has awarded a community...

STHS Edinburg Expanding Robotic Surgery Program with Acquisition of Da Vinci 5 System

Mega Doctor News For the last decade, South Texas Health System Edinburg – the...

Key DNA Complex Connected to PARP Inhibitor Cancer-Drug Resistance Discovered

Mega Doctor News UT Health San Antonio Scientists at The University of Texas Health...
- Advertisement -
×